Form 4: ALX Oncology CMO Barbara Klencke Receives Option Grant

ALX Oncology Holdings Inc. Chief Medical Officer Barbara Klencke was granted 100,000 stock options on April 16, 2026.

Summary

• Chief Medical Officer Barbara Klencke received a grant of 100,000 stock options.
• The options have an exercise price of $1.68 per share.
• The options expire on April 15, 2036.
• Vesting begins on February 25, 2027, with one-fourth of the shares vesting then and the remainder vesting in equal monthly installments over the following 36 months.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of executive interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future shareholder dilution upon the exercise of these options.

Risks

• Market volatility affecting the value of equity compensation.
• Dependence on clinical trial success to drive share price above the $1.68 exercise price.

Future Outlook

The grant indicates a long-term retention strategy for the Chief Medical Officer, aligning her interests with the company's performance over the next decade.

Industry Context

StockSavvy.ai notes that equity grants for C-suite executives in the biotechnology sector are standard practice to ensure leadership retention during critical clinical development phases.

Comparison to Industry Standards

• The use of a 4-year vesting schedule with a 1-year cliff is consistent with standard corporate governance practices for executive compensation in the U.S. biotech industry.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of the first tranche of options on February 25, 2027.

Key Dates

Keywords

ALXO, ALX Oncology, Insider Trading, Stock Options, Executive Compensation, Biotech